The study will aim to confirm preclinical data showing that IL-1 blockade administered to the mother and/or newborn will alleviate the heavy burden of multisystemic developmental disabilities arising from bronchopulmonary dysplasia, NEC, and perinatal white matter injuries all caused by the IL-1-driven fetal inflammatory response arising from CA [140,142]. Here, IL1B is linked to developmental disability.